Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and Obstetrics 2009 stage IB1-IIA) after neoadjuvant chemotherapy.

Tesfai FM, Kroep JR, Gaarenstroom K, De Kroon C, Van Loenhout R, Smit V, Trimbos B, Nout RA, van Poelgeest MIE, Beltman JJ.

Int J Gynecol Cancer. 2019 Nov 19. pii: ijgc-2019-000647. doi: 10.1136/ijgc-2019-000647. [Epub ahead of print]

PMID:
31744889
2.

Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer.

Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, Fruytier SE, Meershoek-Klein Kranenbarg E, Kloet SL, van der Burg B, Martens JWM, Sims AH, Turnbull AK, Dixon JM, Verhaegh W, Kroep JR, van de Velde CJH, van de Stolpe A.

Mol Cancer Ther. 2019 Nov 14. pii: molcanther.0318.2019. doi: 10.1158/1535-7163.MCT-19-0318. [Epub ahead of print]

PMID:
31727690
3.

Validity and Reliability of the Japanese Version of the 10-Item Perceived Efficacy in Patient-Physician Interactions (PEPPI-10) Scale in Breast Cancer Outpatients.

Matsuda A, Inoue K, Momiyama M, Kobayashi K, Kubota K, Ohkubo T, Fischer MJ, Kroep JR, Ramai SSRS, Kaptein AA, Yamaoka K.

Tohoku J Exp Med. 2019 Oct;249(2):121-126. doi: 10.1620/tjem.249.121.

4.

Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies.

Woei-A-Jin FJSH, Zheng SZ, Kiliçsoy I, Hudig F, Luelmo SAC, Kroep JR, Lamb HJ, Osanto S.

Oncologist. 2019 Aug 27. pii: theoncologist.2019-0222. doi: 10.1634/theoncologist.2019-0222. [Epub ahead of print]

PMID:
31455748
5.

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Pijl H, Charehbili A, van de Ven S, Smit VTHBM, Meershoek-Klein Kranenbarg E, Heijns JB, van Warmerdam LJC, Kessels LW, Dercksen MW, Pepels MJAE, van Laarhoven HWM, Vriens BEPJ, Putter H, Fiocco M, Liefers GJ, van der Hoeven JJM, Nortier JWR, Kroep JR; Dutch Breast Cancer Research Group.

Breast Cancer Res. 2019 Aug 28;21(1):97. doi: 10.1186/s13058-019-1180-6.

6.

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.

Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators.

Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. doi: 10.1136/ijgc-2019-000370. Epub 2019 Aug 15.

PMID:
31420414
7.

Effects of short-term fasting on cancer treatment.

de Groot S, Pijl H, van der Hoeven JJM, Kroep JR.

J Exp Clin Cancer Res. 2019 May 22;38(1):209. doi: 10.1186/s13046-019-1189-9. Review.

8.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
9.

Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.

Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, Gelderblom H.

Oncologist. 2019 Jul;24(7):889-e421. doi: 10.1634/theoncologist.2019-0280. Epub 2019 Apr 30.

10.

Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.

Noordhoek I, de Groot AF, Cohen D, Liefers GJ, Portielje JEA, Kroep JR.

Breast Cancer Res Treat. 2019 Jul;176(1):27-36. doi: 10.1007/s10549-019-05233-9. Epub 2019 Apr 17. Review.

11.

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.

de Groot AF, Blok EJ, Charehbili A, Engels CC, Smit VTHBM, Dekker-Ensink NG, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Liefers GJ, Nortier JWR, Kuppen PJK, van der Burg SH, Kroep JR.

Breast Cancer Res Treat. 2019 Jun;175(3):605-615. doi: 10.1007/s10549-019-05195-y. Epub 2019 Mar 13.

12.

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.

van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Int J Cancer. 2019 Sep 1;145(5):1325-1333. doi: 10.1002/ijc.32205. Epub 2019 Mar 4.

13.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
14.

Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer.

Horeweg N, Creutzberg CL, Rijkmans EC, Laman MS, Velema LA, Coen VLMA, Stam TC, Kerkhof EM, Kroep JR, de Kroon CD, Nout RA.

Int J Gynecol Cancer. 2019 Jan 10. pii: ijgc-2018-000057. doi: 10.1136/ijgc-2018-000057. [Epub ahead of print]

PMID:
30630883
15.

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Int J Cancer. 2019 Jul 1;145(1):274-283. doi: 10.1002/ijc.32093. Epub 2019 Jan 16.

16.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
17.

Effects of controlled ovarian stimulation on toxicity of TAC chemotherapy in early breast cancer patients.

de Groot S, Louwé LA, Ramautar AI, Portielje JE, Ogilvie AC, Batman E, Fiocco M, Kroep JR.

Cancer Manag Res. 2018 Sep 26;10:3931-3935. doi: 10.2147/CMAR.S151905. eCollection 2018.

18.

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.

Santegoets SJAM, de Groot AF, Dijkgraaf EM, Simões AMC, van der Noord VE, van Ham JJ, Welters MJP, Kroep JR, van der Burg SH.

Oncoimmunology. 2018 May 31;7(8):e1465166. doi: 10.1080/2162402X.2018.1465166. eCollection 2018.

19.

Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.

de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, Ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ.

J Mol Diagn. 2018 Sep;20(5):600-611. doi: 10.1016/j.jmoldx.2018.05.005. Epub 2018 Jun 21.

20.

Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.

Blok EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, Putter H, Smit VTHBM, Liefers GJ, Morden JP, Bliss JM, Coombes RC, Bartlett JMS, Kroep JR, van de Velde CJH, Kuppen PJK.

Breast Cancer Res Treat. 2018 Aug;171(1):65-74. doi: 10.1007/s10549-018-4785-z. Epub 2018 May 15.

PMID:
29766362
21.

Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL and TEAM Study Groups.

Eur J Cancer. 2018 May;95:59-67. doi: 10.1016/j.ejca.2018.03.014. Epub 2018 Apr 7.

PMID:
29635145
22.

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, Kitzen JJEM, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx074.

PMID:
29546343
23.

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL Study Group.

Breast Cancer Res Treat. 2018 Apr;168(2):413-420. doi: 10.1007/s10549-017-4601-1. Epub 2017 Dec 12.

24.

Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.

Blok EJ, Bastiaannet E, van den Hout WB, Liefers GJ, Smit VTHBM, Kroep JR, van de Velde CJH.

Cancer Treat Rev. 2018 Jan;62:74-90. doi: 10.1016/j.ctrv.2017.10.012. Epub 2017 Nov 6. Review.

25.

The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.

de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR.

Cancer Treat Rev. 2018 Jan;62:18-28. doi: 10.1016/j.ctrv.2017.10.010. Epub 2017 Nov 2. Review.

26.

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.

Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators.

Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

PMID:
29031778
27.

CDK4/6 inhibition in early and metastatic breast cancer: A review.

de Groot AF, Kuijpers CJ, Kroep JR.

Cancer Treat Rev. 2017 Nov;60:130-138. doi: 10.1016/j.ctrv.2017.09.003. Epub 2017 Sep 20. Review.

PMID:
28961554
28.

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok AE, Liefers GJ, Nortier JWR, Rutgers EJT, van de Velde CJH; IDEAL Study Group.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx134.

PMID:
28922787
29.

Cross-cultural comparison of breast cancer patients' Quality of Life in the Netherlands and Japan.

Fischer MJ, Inoue K, Matsuda A, Kroep JR, Nagai S, Tozuka K, Momiyama M, Weijl NI, Langemeijer-Bosman D, Ramai SRS, Nortier JWR, Putter H, Yamaoka K, Kubota K, Kobayashi K, Kaptein AA.

Breast Cancer Res Treat. 2017 Nov;166(2):459-471. doi: 10.1007/s10549-017-4417-z. Epub 2017 Jul 31.

30.

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.

Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH.

Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18.

PMID:
28732650
31.

Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy.

de Groot S, Gelderblom H, Fiocco M, Bovée JV, van der Hoeven JJ, Pijl H, Kroep JR.

Onco Targets Ther. 2017 Jun 13;10:2963-2970. doi: 10.2147/OTT.S123726. eCollection 2017.

32.

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.

Vriens BEPJ, Keymeulen KBMI, Kroep JR, Charehbili A, Peer PG, de Boer M, Aarts MJB, Heuts EM, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Oncotarget. 2017 Jul 11;8(28):46557-46564. doi: 10.18632/oncotarget.15101.

33.

Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.

Blok EJ, van den Bulk J, Dekker-Ensink NG, Derr R, Kanters C, Bastiaannet E, Kroep JR, van de Velde CJ, Kuppen PJ.

Oncotarget. 2017 Feb 28;8(9):15610-15620. doi: 10.18632/oncotarget.14779.

34.

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).

Fontein DB, Charehbili A, Nortier JW, Putter H, Kranenbarg EM, Kroep JR, Linn SC, van de Velde CJ.

Eur J Surg Oncol. 2017 Apr;43(4):619-624. doi: 10.1016/j.ejso.2016.07.146. Epub 2016 Dec 10.

PMID:
28017458
35.

Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer.

Engelhardt EG, Pieterse AH, Han PK, van Duijn-Bakker N, Cluitmans F, Maartense E, Bos MM, Weijl NI, Punt CJ, Quarles van Ufford-Mannesse P, Sleeboom H, Portielje JE, van der Hoeven KJ, Woei-A-Jin FJ, Kroep JR, de Haes HC, Smets EM, Stiggelbout AM.

Med Decis Making. 2017 Apr;37(3):179-192. doi: 10.1177/0272989X16670639. Epub 2016 Sep 29.

PMID:
27681991
36.

Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making.

Engelhardt EG, Pieterse AH, van der Hout A, de Haes HJ, Kroep JR, Quarles van Ufford-Mannesse P, Portielje JE, Smets EM, Stiggelbout AM.

Eur J Cancer. 2016 Oct;66:55-66. doi: 10.1016/j.ejca.2016.07.011. Epub 2016 Aug 15.

PMID:
27525573
37.

Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective.

Pieterse AH, Kunneman M, Engelhardt EG, Brouwer NJ, Kroep JR, Marijnen CAM, Stiggelbout AM, Smets EMA.

Psychooncology. 2017 Jul;26(7):943-950. doi: 10.1002/pon.4241. Epub 2016 Sep 15.

PMID:
27502561
38.

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.

Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S.

Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17.

39.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH.

Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.

PMID:
27075626
40.

Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care.

Kool M, van der Sijp JR, Kroep JR, Liefers GJ, Jannink I, Guicherit OR, Vree R, Bastiaannet E, van de Velde CJ, Marang-van de Mheen PJ.

Breast. 2016 Jun;27:62-8. doi: 10.1016/j.breast.2016.02.015. Epub 2016 Mar 26.

PMID:
27026219
41.

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.

Engels CC, Kiderlen M, Bastiaannet E, van Eijk R, Mooyaart A, Smit VT, de Craen AJ, Kuppen PJ, Kroep JR, van de Velde CJ, Liefers GJ.

Breast Cancer Res Treat. 2016 Apr;156(2):361-70. doi: 10.1007/s10549-016-3734-y. Epub 2016 Mar 11.

42.

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.

Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3.

43.

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.

Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JWR, Kohno N.

Eur J Cancer. 2016 Feb;54:57-63. doi: 10.1016/j.ejca.2015.10.011. Epub 2015 Dec 23.

44.

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).

Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).

Breast. 2016 Feb;25:69-74. doi: 10.1016/j.breast.2015.10.005. Epub 2015 Nov 21.

PMID:
26614548
45.

We're in this together: Patients', caregivers' and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC).

Kaptein AA, Kobayashi K, Matsuda A, Kubota K, Nagai S, Momiyama M, Sugisaki M, Bos BC, Warning TD, Dik H, Klink Rv, Inoue K, Ramai R, Taube C, Kroep JR, Fischer MJ.

Lung Cancer. 2015 Dec;90(3):575-81. doi: 10.1016/j.lungcan.2015.10.017. Epub 2015 Oct 19. Review.

PMID:
26520188
46.

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.

de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, Pijl H, Kroep JR.

BMC Cancer. 2015 Oct 5;15:652. doi: 10.1186/s12885-015-1663-5.

47.

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH.

Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772.

48.

Illness Perceptions in Women with Breast Cancer-a Systematic Literature Review.

Kaptein AA, Schoones JW, Fischer MJ, Thong MS, Kroep JR, van der Hoeven KJ.

Curr Breast Cancer Rep. 2015;7(3):117-126. Review.

49.

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

Charehbili A, de Groot S, van der Straaten T, Swen JJ, Pijl H, Gelderblom H, van de Velde CJ, Nortier JW, Guchelaar HJ, Kroep JR.

Pharmacogenomics. 2015;16(11):1267-76. doi: 10.2217/PGS.15.74. Epub 2015 Aug 20.

PMID:
26289095
50.

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR.

Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27.

PMID:
26216383

Supplemental Content

Loading ...
Support Center